# Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine

> **NCT02823899** · PHASE1,PHASE2 · COMPLETED · sponsor: **International Centre for Diarrhoeal Disease Research, Bangladesh** · enrollment: 840 (actual)

## Conditions studied

- Cholera

## Interventions

- **BIOLOGICAL:** HL-OCV
- **BIOLOGICAL:** Shanchol

## Key facts

- **NCT ID:** NCT02823899
- **Lead sponsor:** International Centre for Diarrhoeal Disease Research, Bangladesh
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2017-11
- **Final completion:** 2017-11
- **Target enrollment:** 840 (ACTUAL)
- **Last updated:** 2018-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02823899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02823899, "Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02823899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*